These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 10565912

  • 1. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.
    Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH.
    J Clin Microbiol; 1999 Dec; 37(12):3946-51. PubMed ID: 10565912
    [Abstract] [Full Text] [Related]

  • 2. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
    Pfaller MA, Messer SA, Hollis RJ, Jones RN, SENTRY Participants Group.
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
    Wang HC, Hsieh MI, Choi PC, Wu CJ.
    J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
    [Abstract] [Full Text] [Related]

  • 4. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM.
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [Abstract] [Full Text] [Related]

  • 5. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
    Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH.
    J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
    [Abstract] [Full Text] [Related]

  • 6. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
    Lewis RE, Wiederhold NP, Klepser ME.
    Antimicrob Agents Chemother; 2005 Mar; 49(3):945-51. PubMed ID: 15728887
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species.
    Misra R, Malik A, Singhal S.
    Indian J Pathol Microbiol; 2011 Mar; 54(1):112-6. PubMed ID: 21393890
    [Abstract] [Full Text] [Related]

  • 8. In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs.
    Pfaller JB, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA.
    J Clin Microbiol; 2003 Mar; 41(3):1126-9. PubMed ID: 12624040
    [Abstract] [Full Text] [Related]

  • 9. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.
    Verweij PE, Mensink M, Rijs AJ, Donnelly JP, Meis JF, Denning DW.
    J Antimicrob Chemother; 1998 Sep; 42(3):389-92. PubMed ID: 9786480
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
    Cuenca-Estrella M, Rodríguez-Tudela JL, Mellado E, Martínez-Suárez JV, Monzón A.
    J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
    [Abstract] [Full Text] [Related]

  • 11. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD, Kiraz N.
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis.
    Lalitha P, Shapiro BL, Srinivasan M, Prajna NV, Acharya NR, Fothergill AW, Ruiz J, Chidambaram JD, Maxey KJ, Hong KC, McLeod SD, Lietman TM.
    Arch Ophthalmol; 2007 Jun; 125(6):789-93. PubMed ID: 17562990
    [Abstract] [Full Text] [Related]

  • 13. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
    Philip A, Odabasi Z, Rodriguez J, Paetznick VL, Chen E, Rex JH, Ostrosky-Zeichner L.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3572-4. PubMed ID: 16048988
    [Abstract] [Full Text] [Related]

  • 14. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J, Peláez T, Alcalá L, Bouza E.
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):273-6. PubMed ID: 17141455
    [Abstract] [Full Text] [Related]

  • 15. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J, Peláez T, Alcalá L, Bouza E.
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953
    [Abstract] [Full Text] [Related]

  • 16. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
    Espinel-Ingroff A.
    J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
    [Abstract] [Full Text] [Related]

  • 17. EUCAST Determination of Olorofim (F901318) Susceptibility of Mold Species, Method Validation, and MICs.
    Jørgensen KM, Astvad KMT, Hare RK, Arendrup MC.
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784842
    [Abstract] [Full Text] [Related]

  • 18. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B.
    Oakley KL, Moore CB, Denning DW.
    J Antimicrob Chemother; 1998 Jul; 42(1):91-4. PubMed ID: 9700534
    [Abstract] [Full Text] [Related]

  • 19. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
    Johnson EM, Szekely A, Warnock DW.
    J Antimicrob Chemother; 1998 Dec; 42(6):741-5. PubMed ID: 10052897
    [Abstract] [Full Text] [Related]

  • 20. [In vitro activity of amphotericin B, itraconazole and voriconazole against 20 species of Aspergillus using the Sensititre microdilution method].
    García-Martos P, García-Agudo L, Gutiérrez-Calzada J, Ruiz-Aragón J, Saldarreaga A, Marín P.
    Enferm Infecc Microbiol Clin; 2005 Jan; 23(1):15-8. PubMed ID: 15701327
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.